Skip to main
NVAX

Novavax (NVAX) Stock Forecast & Price Target

Novavax (NVAX) Analyst Ratings

Based on 6 analyst ratings
Buy
Strong Buy 50%
Buy 17%
Hold 17%
Sell 17%
Strong Sell 0%

Bulls say

Novavax is positioned favorably because Matrix-M appears to be a differentiated, human-use adjuvant with a potentially safer profile and broad applicability, which can support both internal pipeline development and high-value external partnerships across infectious disease and oncology. Its collaboration momentum is notable, with four top-ten global pharmaceutical companies and 30+ unique fields under exploration, while Nuvaxovid’s commercial profile remains attractive through high-teens to low-20s royalties, encouraging Q1:26 sales of €16MM, and projected 19% to 26% standalone COVID-19 market share by 2030. The outlook is further supported by an estimated $40-50MM in 2026 product supply sales and a target for a $200MM core-expense run-rate, which together suggest improving operating leverage and multiple avenues for value creation.

Bears say

Novavax is viewed negatively because its core COVID-19 vaccine opportunity appears to be shrinking, with surveyed physicians expecting an 11% decline in vaccinated U.S. adults in the 2026-27 season and IQVIA Rx data indicating roughly a 26% decline in COVID-19 vaccine prescriptions through 12/26/25. At the same time, new FDA/CDC guidelines implemented in '25 limit access for people without risk factors, while market-share expectations for Nuvaxovid in 2030 remain only 19% from physicians and 26% from payors, underscoring constrained commercial upside. Beyond demand pressure, the company still faces typical biotech risks—clinical safety surprises, regulatory delays, IP challenges, and failure to develop a successful combo or variant-specific boosters—making execution and valuation highly uncertain.

Novavax (NVAX) has been analyzed by 6 analysts, with a consensus rating of Buy. 50% of analysts recommend a Strong Buy, 17% recommend Buy, 17% suggest Holding, 17% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Novavax and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Novavax (NVAX) Forecast

Analysts have given Novavax (NVAX) a Buy based on their latest research and market trends.

According to 6 analysts, Novavax (NVAX) has a Buy consensus rating as of Oct 8, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $14, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $14, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Novavax (NVAX)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.